Key result
CD36 deficiency raises inactive-period blood pressure via the renal AMPK/HDAC5/PER1 pathway.
Why the study?
Nocturnal hypertension is a strong predictor of cardio-cerebrovascular disease, yet its underlying mechanisms remain largely unknown.
Does CD36 deficiency disrupt circadian blood pressure rhythms and promote nocturnal hypertension via the renal AMPK/HDAC5/PER1 pathway?
Does CD36 deficiency disrupt circadian blood pressure rhythms and promote nocturnal hypertension via the renal AMPK/HDAC5/PER1 pathway?
Identifies renal CD36 as a key regulator of circadian blood pressure rhythms via the AMPK/HDAC5/PER1 axis and a potential biomarker and therapeutic target for nocturnal hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for renal CD36 as nocturnal hypertension target; leaves open human validation before clinical consideration.
BACKGROUND: Nocturnal hypertension is a strong predictor of cardio-cerebrovascular disease, yet its underlying mechanisms remain largely unknown. In this study, we identified CD36 as a key regulator of blood pressure (BP) rhythms and as a gatekeeper of nocturnal hypertension. Its deficiency disrupts circadian BP rhythms. METHODS: We continuously monitored 48-hour BP using telemetry in CD36 global knockout mice and renal proximal tubule-specific CD36 knockout mice. We also collected serum samples and ambulatory BP monitoring data from patients with nocturnal hypertension to assess the relationship between CD36 expression and nocturnal hypertension. A comprehensive screening of various factors affecting BP and circadian rhythms was conducted to explore the molecular mechanisms. RESULTS: Our telemetry data revealed significantly elevated BP during the daytime (inactive period) in both CD36 global knockout and renal proximal tubule-specific knockout mice compared with their control counterparts. Furthermore, levels of platelet CD36 were negatively correlated with the severity of nocturnal hypertension in humans. Mechanistically, CD36 modulates BP rhythms through the AMPK (AMP-activated protein kinase)/HDAC5 (histone deacetylase 5)/PER1 pathway: its deficiency activates phosphorylated AMPK, leading to the dissociation of the HDAC5-PER1 complex, enhancing PER1 nuclear accumulation, and desynchronizing the oscillations of intrarenal renin-angiotensin-aldosterone system genes and clock-controlled genes, ultimately disrupting BP rhythm. CONCLUSIONS: Our findings highlight CD36 as a critical integrator that links renal clocks to BP homeostasis, establishing it as a potential predictor and therapeutic target for nocturnal hypertension.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied Nocturnal hypertension. CD36 deficiency (global or renal proximal tubule-specific knockout / lower platelet CD36 levels) vs. Control counterpart mice was evaluated on 48-hour circadian blood pressure rhythm and inactive-period (daytime in mice / nocturnal in humans) blood pressure. CD36 deficiency in global and renal proximal tubule-specific knockout mice significantly elevated inactive-period BP during 48-hour telemetry via the renal AMPK/HDAC5/PER1 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: